Medicenna Therapeutics Corp Stock Book Value Per Share
| MDNA Stock | CAD 0.84 0.02 2.33% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Medicenna Therapeutics' long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.25 | 0.25 | |
| Tangible Book Value Per Share | 0.25 | 0.25 |
Medicenna | Book Value Per Share |
Medicenna Therapeutics Corp Company Book Value Per Share Analysis
Medicenna Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Medicenna Therapeutics Book Value Per Share | 0.18 X |
Most of Medicenna Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medicenna Therapeutics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Medicenna Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Medicenna Therapeutics is extremely important. It helps to project a fair market value of Medicenna Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Medicenna Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Medicenna Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Medicenna Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Medicenna Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Medicenna Therapeutics Corp is about 0.177 times. This is 110.41% lower than that of the Biotechnology sector and 100.07% lower than that of the Health Care industry. The book value per share for all Canada stocks is 99.99% higher than that of the company.
Medicenna Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medicenna Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medicenna Therapeutics could also be used in its relative valuation, which is a method of valuing Medicenna Therapeutics by comparing valuation metrics of similar companies.Medicenna Therapeutics is currently under evaluation in book value per share category among its peers.
Medicenna Fundamentals
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 45.37 M | ||||
| Shares Outstanding | 83.38 M | ||||
| Shares Owned By Insiders | 20.76 % | ||||
| Shares Owned By Institutions | 11.82 % | ||||
| Number Of Shares Shorted | 49.75 K | ||||
| Price To Book | 3.67 X | ||||
| EBITDA | (21.84 M) | ||||
| Net Income | (11.8 M) | ||||
| Cash And Equivalents | 24.84 M | ||||
| Cash Per Share | 0.83 X | ||||
| Total Debt | 9.29 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 26.75 X | ||||
| Book Value Per Share | 0.18 X | ||||
| Cash Flow From Operations | (16.49 M) | ||||
| Short Ratio | 1.91 X | ||||
| Earnings Per Share | (0.15) X | ||||
| Target Price | 4.38 | ||||
| Number Of Employees | 18 | ||||
| Beta | 1.69 | ||||
| Market Capitalization | 70.04 M | ||||
| Total Asset | 28.38 M | ||||
| Retained Earnings | (118.25 M) | ||||
| Working Capital | 23.74 M | ||||
| Net Asset | 28.38 M |
About Medicenna Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medicenna Therapeutics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medicenna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medicenna Therapeutics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Medicenna Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medicenna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medicenna Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Medicenna Stock
| 0.88 | TD | Toronto Dominion Bank | PairCorr |
| 0.84 | RY-PN | Royal Bank | PairCorr |
| 0.84 | ECOR | Ecora Resources plc | PairCorr |
| 0.8 | RY-PO | Royal Bank | PairCorr |
| 0.79 | SES | Secure Energy Services | PairCorr |
The ability to find closely correlated positions to Medicenna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medicenna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medicenna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medicenna Therapeutics Corp to buy it.
The correlation of Medicenna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medicenna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medicenna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medicenna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medicenna Stock
Medicenna Therapeutics financial ratios help investors to determine whether Medicenna Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medicenna with respect to the benefits of owning Medicenna Therapeutics security.